Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
362 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07842887 | Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance(A Phase 1 Clin) | not yet recruiting | Phase 1 | 24 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07429318 | Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer(GC/GEJC) | active not recruiting | — | 300 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| 1 |
| Sep 22, 2026 |
| clinicaltrials |
| NCT07835035 | Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy | recruiting | Phase 1 | 12 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07147361 | Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma(PB-PD1R-SCC) | active not recruiting | — | 800 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06146946 | Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H) | recruiting | N/A | 1,384 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819669 | Video-Assisted Thoracoscopic Surgery Combined With Radiofrequency Ablation Versus VATS Alone for Multiple Primary Lung Cancer | not yet recruiting | N/A | 160 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07557251 | A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma | recruiting | Phase 1 | 21 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07791602 | Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer(IDEAL-RT) | active not recruiting | Phase 2 | 180 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07791615 | A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma | not yet recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07793500 | YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC) | recruiting | Early Phase 1 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05254899 | A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)(CLCG-2102) | completed | Phase 2 | 54 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07773818 | Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study | recruiting | — | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06910072 | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer(UPGRADE-TNBC)(UPGRADE-TNBC) | enrolling by invitation | Phase 2 / Phase 3 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06993506 | Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer | recruiting | — | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07749859 | SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07743749 | An MRI-Based Study of Intelligent Pathological Subtyping and Grading of Renal Tumors | recruiting | — | 900 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07735858 | Microfluidic Urinary Exosome-Based Diagnostic Model for Bladder Cancer | active not recruiting | — | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06417892 | Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma | recruiting | — | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06038461 | An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors | recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07373899 | Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study | enrolling by invitation | — | 354 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07724223 | Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC | recruiting | Phase 2 | 46 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07725653 | Impact of Anterior Urethral Suspension Combined With Pelvic Fascia Reconstruction During Robot-Assisted Radical Prostatectomy on Early Postoperative Urinary Continence Recovery: A Single-Center, Prospective, Single-Arm Clinical Study(IAPREA) | completed | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07719738 | Bevacizumab Plus Nab-paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsule (S-1) as Second-line Treatment for Advanced Biliary Tract Cancer: a Phase Ⅱ Clinical Trial | completed | Phase 2 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07711470 | Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC(SCOPE) | active not recruiting | Phase 2 | 140 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07692152 | Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma | recruiting | Phase 3 | 350 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07689851 | Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer | recruiting | Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07672743 | A Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer | not yet recruiting | N/A | 29 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07366658 | Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients(NEUK203-13) | recruiting | Phase 1 | 9 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668037 | Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy | recruiting | — | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07636824 | Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study | recruiting | Phase 2 | 92 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07084519 | Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction | recruiting | Phase 3 | 506 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07656090 | Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors | enrolling by invitation | Early Phase 1 | 19 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07656103 | QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors | not yet recruiting | Early Phase 1 | 7 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07656116 | Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors | recruiting | Phase 1 | 27 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657390 | Prospective Randomized Controlled Clinical Study of Acupoint Application With Gutong Plaster in the Treatment of Moderate to Severe Cancer Pain | recruiting | Phase 1 / Phase 2 | 198 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657403 | CONNEctome-guided Navigation for Eloquent-area Tumor Surgery Trial(CONNECT Trail) | recruiting | N/A | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657442 | Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer | not yet recruiting | N/A | 649 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657494 | Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study | recruiting | N/A | 94 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657585 | CIB In Vivo CAR-T Lentiviral Injection in Patients With Advanced Malignant Tumors | not yet recruiting | Phase 1 | 91 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657611 | Inhaled mRNA Immunotherapy for Patients With Advanced Lung Cancer or Pulmonary Metastatic Solid Tumors(BMD-PLAT) | not yet recruiting | Early Phase 1 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 18, 2026 | clinicaltrials |
| NCT06189183 | Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection | active not recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06501976 | An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment | active not recruiting | Phase 2 | 9 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07187154 | The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy | recruiting | N/A | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07650825 | OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07650838 | OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS) | not yet recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT06771609 | Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. | recruiting | Phase 2 | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06839547 | A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis. | recruiting | — | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06839560 | Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis | recruiting | Phase 2 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06908668 | Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer | recruiting | Phase 2 | 170 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06776861 | A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer | recruiting | — | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 9, 2026 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials